Dr. Gabriel N. Mannis, MD
Medical Oncology (Medical Oncology Physician)
300 Pasteur Dr
Stanford, CA 94305
Who else practices at this address →
Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, Davis School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 132
Licensed in California since 2010, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: University of California, Davis School of Medicine
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
CA license A110736 (first issued 2010; current) -
Hematology (Internal Medicine) Physician
CA license A110736 (first issued 2010; current) -
Hematology & Oncology Physician
CA license A110736 (first issued 2010; current) -
Internal Medicine Physician
CA license A110736 (first issued 2010; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Stanford Health Care Stanford, CA
- UCSF Medical Center San Francisco, CA
- Stanford Health Care Tri-Valley Pleasanton, CA
Medical groups
- Stanford Health Care (3,122 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 132
- Services billed
- 696
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 292 | 57 |
| Established patient office or other outpatient visit, 40-54 minutes | 231 | 62 |
| Established patient office or other outpatient visit, 30-39 minutes | 186 | 69 |
| Hospital discharge day management, more than 30 minutes | 38 | 30 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 37 | 33 |
| New patient office or other outpatient visit, 60-74 minutes | 23 | 23 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Venclexta (venetoclax) | 57 |
| Inqovi (decitabine/cedazuridine) | 18 |
| Tibsovo (ivosidenib) | 18 |
| Allopurinol Other prescribers in Stanford, CA | 11 |
| Cresemba (isavuconazonium sulfate) | 11 |
| Vanflyta (quizartinib dihydrochloride) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 27 payments worth $29,416 in total to this clinician.
| AbbVie Inc. | $9,290 |
|---|---|
| Taiho Oncology, Inc. | $3,900 |
| Astellas Pharma Global Development | $3,718 |
| Daiichi Sankyo Inc. | $3,393 |
| Janssen Scientific Affairs, LLC | $2,659 |
| Stemline Therapeutics Inc. | $2,340 |
| Genentech USA, Inc. | $1,847 |
| Syndax Pharmaceuticals, Inc. | $800 |
| Consulting Fee | $27,877 |
|---|---|
| Food and Beverage | $854 |
| Honoraria | $685 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Taiho Oncology, Inc. Feb 19, 2025 | Consulting Fee INQOVI · Oncology | $3,900 |
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $3,225 |
| Astellas Pharma Global Development Apr 30, 2025 | Consulting Fee Xospata · Oncology | $2,704 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Stemline Therapeutics Inc. Apr 18, 2025 | Consulting Fee ELZONRIS · Oncology | $2,340 |
| AbbVie Inc. Jan 2, 2025 | Consulting Fee | $2,100 |
| AbbVie Inc. Dec 19, 2025 | Consulting Fee | $2,100 |
| AbbVie Inc. Feb 20, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,750 |
| AbbVie Inc. Jan 17, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,725 |
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,640 |
All 16 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Daiichi Sankyo Inc. Dec 23, 2025 | Consulting Fee Vanflyta · ONCOLOGY | $3,225 |
| Syndax Pharmaceuticals, Inc. Dec 22, 2025 | Consulting Fee REVUFORJ · HEMATOLOGY-ONCOLOGY | $800 |
| AbbVie Inc. Dec 19, 2025 | Consulting Fee | $2,100 |
| Genentech USA, Inc. Dec 6, 2025 | Consulting Fee Venclexta · BioOncology | $1,640 |
| Astellas Pharma US Inc Oct 17, 2025 | Consulting Fee Xospata · Oncology | $676 |
| Janssen Scientific Affairs, LLC Sep 23, 2025 | Consulting Fee | $2,503 |
| Rigel Pharmaceuticals, Inc. Sep 5, 2025 | Honoraria Rezlidhia · Acute Myeloid Leukemia | $685 |
| AbbVie Inc. May 28, 2025 | Consulting Fee | $700 |
| Astellas Pharma Global Development Apr 30, 2025 | Consulting Fee Xospata · Oncology | $2,704 |
| Stemline Therapeutics Inc. Apr 18, 2025 | Consulting Fee ELZONRIS · Oncology | $2,340 |
| Astellas Pharma Global Development Mar 21, 2025 | Consulting Fee Xospata · Oncology | $1,014 |
| AbbVie Inc. Mar 6, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $700 |
| AbbVie Inc. Feb 20, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,750 |
| Taiho Oncology, Inc. Feb 19, 2025 | Consulting Fee INQOVI · Oncology | $3,900 |
| AbbVie Inc. Jan 17, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $1,725 |
| AbbVie Inc. Jan 2, 2025 | Consulting Fee | $2,100 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $637,398 in research payments for these studies, mostly to the institutions running them.
- ASTX727-07
Taiho Oncology, Inc. - A phase 1/2, open-label, dose-escalation and dose-expansion cohort study of SNDX-5613 in patients with relapsed/refractory leukemias, including those harboring an mll/KMT2A gene rearrangement or nucleophosmin 1 (NPM1)…
Syndax Pharmaceuticals, Inc. - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247 - STML-401-0423 - a phase ii multicenter open -label trial of tagraxofusp (tag) in combination with venetoclax and azacitidine (ven/aza) in adults with previously untreated CD123+ acute myeloid leukemia (aml) who are i…
Stemline Therapeutics Inc. - Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemi…
Taiho Oncology, Inc. - Study name not reported
Siemens Medical Solutions USA, Inc. - Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc. - A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc. · Recruiting · NCT04988555
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.